• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Merit Medical Systems Inc.

    6/27/25 4:22:13 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care
    Get the next $MMSI alert in real time by email
    11-K 1 mmsi-20241231x11k.htm 11-K

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    ​

    FORM 11-K

    ​

    ​

    ☒ Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934

    ​

    For the fiscal year ended December 31, 2024

    ​

    OR

    ​

    ☐ Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934

    ​

    For the transition period from        to

    ​

    Commission File Number: 0-18592

    ​

    A. Full title of the plan and the address of the plan, if different from that of the issuer named below:

    ​

    MERIT MEDICAL SYSTEMS, INC. 401(k) PROFIT SHARING PLAN

    ​

    B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

    ​

     Graphic

    ​

    Merit Medical Systems, Inc.

    1600 West Merit Parkway

    South Jordan, Utah 84095

    ​

    ​

    ​

    ​

    ​


    Table of Contents

    ​

    MERIT MEDICAL SYSTEMS, INC. 401(k) PROFIT SHARING PLAN

    TABLE OF CONTENTS

    ​

    ​

    ​

    ​

    Page

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

    1

    ​

    ​

    FINANCIAL STATEMENTS:

    ​

    Statements of Net Assets Available for Benefits as of December 31, 2024 and 2023

    2

    Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2024

    3

    Notes to Financial Statements

    4

    ​

    ​

    SUPPLEMENTAL SCHEDULE:

    ​

    Form 5500, Schedule H, Part IV, Line 4i — Schedule of Assets (Held at End of Year) as of December 31, 2024

    9

    ​

    ​

    EXHIBIT INDEX:

    11

    Exhibit 23.1 - Consent of Independent Registered Public Accounting Firm

    11

    ​

    ​

    SIGNATURES:

    12

    ​

    ​

    ​

    NOTE:   All other schedules required by Section 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 have been omitted because they are not applicable.

    ​

    ​

    ​


    Table of Contents

    ​

    ​

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

    ​

    To the Plan Participants and Plan Administrator of Merit Medical Systems, Inc. 401(k) Profit Sharing Plan

    Opinion on the Financial Statements

    ​

    We have audited the accompanying statements of net assets available for benefits of Merit Medical Systems, Inc. 401(k) Profit Sharing Plan (the "Plan") as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

    ​

    Basis for Opinion

    ​

    These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on the Plan's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    ​

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    ​

    Report on Supplemental Schedule

    ​

    The supplemental schedule of assets (held at end of year) as of December 31, 2024, has been subjected to audit procedures performed in conjunction with the audit of the Plan's financial statements. The supplemental schedule is the responsibility of the Plan's management. Our audit procedures included determining whether the supplemental schedule reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the supplemental schedule, we evaluated whether the supplemental schedule, including its form and content, is presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, such schedule is fairly stated, in all material respects, in relation to the financial statements as a whole.

    ​

    ​

    /s/ DELOITTE & TOUCHE LLP

    ​

    June 27, 2025

    We have served as the auditor of the Plan since 2003.

    ​

    1


    Table of Contents

    ​

    MERIT MEDICAL SYSTEMS, INC. 401(k) PROFIT SHARING PLAN

    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS

    AS OF DECEMBER 31, 2024 AND 2023

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

        

    As of December 31,

    ​

        

    2024

        

    2023

    ASSETS:

     

    ​

    ​

     

    ​

      

    Investments — at fair value

    ​

    $

    213,599,896

    ​

    $

    182,627,805

    ​

    ​

     

    ​

    ​

    ​

    ​

    Receivables:

    ​

     

    ​

    ​

    ​

    ​

    Notes receivable from participants

    ​

     

    3,202,552

    ​

     

    2,657,452

    Employer contributions

    ​

     

    303,191

    ​

     

    393,957

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Total receivables

    ​

     

    3,505,743

    ​

     

    3,051,409

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Total assets

    ​

     

    217,105,639

    ​

     

    185,679,214

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    LIABILITIES:

    ​

     

    ​

    ​

     

    ​

    Excess contributions payable

    ​

     

    271,051

    ​

     

    417,791

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Total liabilities

    ​

     

    271,051

    ​

     

    417,791

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    NET ASSETS AVAILABLE FOR BENEFITS

    ​

    $

    216,834,588

    ​

    $

    185,261,423

    ​

    See accompanying notes to the financial statements.

    ​

    ​

    ​

    2


    Table of Contents

    ​

    MERIT MEDICAL SYSTEMS, INC. 401(k) PROFIT SHARING PLAN

    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

    FOR THE YEAR ENDED DECEMBER 31, 2024

    ​

    ​

    ​

    ​

    ​

    CONTRIBUTIONS

    ​

    ​

    ​

    Employer

    ​

    $

    4,975,364

    Participant

    ​

    ​

    13,664,555

    Rollover

    ​

    ​

    5,988,027

    Total contributions

    ​

    ​

    24,627,946

    ​

    ​

     

    ​

    INVESTMENT INCOME

    ​

    ​

    ​

    Net appreciation in fair value of investments

    ​

     

    26,230,595

    Interest and dividends

    ​

     

    4,851,757

    Total net investment income

    ​

     

    31,082,352

    ​

    ​

    ​

    ​

    Interest income on notes receivable from participants

    ​

     

    218,036

    ​

    ​

    ​

    ​

    DEDUCTIONS

    ​

     

    ​

    Benefits paid to participants

    ​

    ​

    (24,128,386)

    Administrative expenses

    ​

     

    (226,783)

    Total deductions

    ​

     

    (24,355,169)

    ​

    ​

    ​

    ​

    NET INCREASE IN NET ASSETS AVAILABLE FOR BENEFITS

    ​

     

    31,573,165

    ​

    ​

    ​

    ​

    NET ASSETS AVAILABLE FOR BENEFITS:

    ​

    ​

    ​

    Beginning of year

    ​

     

    185,261,423

    ​

    ​

    ​

    ​

    End of year

    ​

    $

    216,834,588

    ​

    See accompanying notes to financial statements.

    ​

    ​

    ​

    3


    Table of Contents

    ​

    MERIT MEDICAL SYSTEMS, INC. 401(k) PROFIT SHARING PLAN

    NOTES TO FINANCIAL STATEMENTS

    AS OF DECEMBER 31, 2024 AND 2023 AND FOR THE YEAR ENDED DECEMBER 31, 2024

    1.     DESCRIPTION OF THE PLAN

    The following description of the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan (the “Plan”) is provided for general information purposes only. Reference should be made to the Plan document for more complete information.

    General — The Plan is a defined contribution plan covering substantially all employees in the United States who have completed 90 days of service for Merit Medical Systems, Inc. (the “Company”). The Board of Directors of the Company has appointed the 401(k) Plan Administration and Investment Committee to control and manage the operation and administration of the Plan. Fidelity Management Trust Company serves as the trustee of the Plan.

    The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

    Contributions — Each year, participants may contribute up to 100% of their eligible compensation, as defined in the Plan, through pre-tax payroll deductions and may make Roth (after-tax) elective deferrals to the Plan, subject to certain limitations under the Internal Revenue Code ("IRC"). The Company may elect to make discretionary matching contributions to the plan. During the year ended December 31, 2024, the Company made matching contributions to the plan, equal to 60% of the first 5% of total compensation that a participant contributed to the Plan. The match is calculated and funded on a per pay period basis with a year-end "true up" for annual compensation, if necessary.

    Participant Accounts — Individual accounts are maintained for each Plan participant. Each participant’s account is credited with the participant’s contributions, the Company’s matching contributions, and Plan earnings, and is charged with withdrawals and an allocation of Plan losses and expenses. Allocations are based on participant earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.

    Investments — Participants direct the investment of their contributions and Company matching contributions into various investment options offered by the Plan and may change investments and transfer amounts between funds daily. The Plan offers fund options with registered investment companies, common-collective trust funds, a stable value fund, shares of the Company's stock, and a participant-directed brokerage account feature. Participants may direct their investments through a trustee-sponsored brokerage account, which offers a variety of mutual funds and the option to invest in individual stocks.

    Vesting — Participants are vested immediately in their contributions, plus actual earnings thereon. Vesting in the Company’s contribution portion of their accounts is based on years of continuous service. A participant vests 20% per year of credited service and is 100% vested after five years of credited service.

    Notes Receivable from Participants — Participants may borrow from their accounts up to a maximum of $50,000 or 50% of their vested account balance, whichever is less. The loans are secured by the balance in the participant’s account and bear interest at rates commensurate with local prevailing rates at the time funds are borrowed as determined by the Plan administrator. Principal and interest are paid on a ratable basis through payroll deductions. Loans outstanding to participants as of December 31, 2024 will mature at various dates through 2032 with interest rates ranging from 4.25% to 9.5%.

    Payment of Benefits — On termination of service due to death, disability or retirement, a participant may elect to receive distributions equal to of the value of the participant’s vested interest in his or her account as a lump-sum amount or installment payments. For termination of service for other reasons, a participant may receive the value of the vested interest in his or her account as a lump-sum distribution.

    4


    Table of Contents

    ​

    Hardship distributions, subject to a $500 minimum, may also be allowed from the participant deferral contribution balance for purchasing a primary residence, financing higher education, paying for necessary medical care, or alleviating certain other financial hardships. 

    Forfeited Accounts — When certain terminations of participation in the Plan occur, the nonvested portion of the participant’s account, as defined by the Plan, represents a forfeiture. As of December 31, 2024 and 2023, forfeited non-vested accounts totaled $74,094 and $130,096, respectively. Forfeitures of participants’ non-vested accounts are used to pay Plan expenses or to reduce future Company matching contributions. During 2024, forfeited nonvested accounts were used by the Plan Administrator to fund Company matching contributions of $109,965 and to fund administrative expenses of $178,176.

    Administrative Expenses — The Plan is sponsored by the Company, and certain administrative expenses of the Plan are paid by the Company as provided in the Plan document.

    ​

    2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    Basis of Accounting — The accompanying financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States of America ("GAAP").

    Use of Estimates — The preparation of financial statements in conformity with GAAP requires Plan management to make estimates and assumptions that affect the reported amounts of net assets available for benefits and changes therein. Actual results could differ from those estimates.

    Risk and Uncertainties — The Plan utilizes various investment instruments. Investment securities, in general, are exposed to various risks, such as interest rate risk, credit risk, and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

    Included in investments at December 31, 2024 and 2023 are shares of the Company’s common stock with a fair value of $47,972,130 and $43,107,310, respectively, held by the Plan within participant accounts. This investment represents 22.5% and 23.6% of total investments at December 31, 2024 and 2023, respectively. A significant decline in the market value of the Company’s stock would significantly affect the net assets available for benefits.

    Contributions — Employee contributions and the related employer matching contributions are recognized during the period in which employee contributions are withheld from compensation. Employee contributions and employer matching contributions that are earned during the Plan year but not yet paid until after the Plan year ended are accrued and recorded as contributions receivable on the statements of net assets available for benefits.

    Payment of Benefits — Benefit payments to participants are recorded upon distribution. There were no amounts allocated to accounts of former participants who elected to withdraw from the Plan but had not been paid at December 31, 2024 and 2023.

    Excess Contributions Payable — The Plan is required to return contributions received during the Plan year in excess of IRC limits. As of December 31, 2024 and 2023, the total excess contribution payable was $271,051 and $417,791, respectively.

    Investment Valuation and Income Recognition — The Plan’s investments are stated at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

    Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net appreciation (depreciation) includes the Plan’s gains and losses on investments bought and sold as well as held during the year.

    5


    Table of Contents

    ​

    Administrative Expenses — Management fees and operating expenses charged to the Plan for investments in mutual funds, common-collective trust funds and the stable value fund are deducted from income earned on a daily basis and are not separately reflected. Consequently, management fees and operating expenses are reflected as a reduction of investment return for such investments. Certain indirect administrative expenses are paid by the Company and are excluded from these financial statements. Expenses paid by the Plan include legal, accounting, trustee, recordkeeping, and other administrative fees and expenses associated with maintaining the Plan and are shown on the Statement of Changes in Net Assets Available for Benefits.

    The Plan has a revenue-sharing agreement whereby certain investment managers return a portion of the investment fees to the recordkeeper to offset the Plan’s administrative expenses. Future Plan expenses can be paid from any excess remaining revenue sharing amounts. For the year ended December 31, 2024, $56,351 was used to offset Plan expenses. The Plan held undistributed administrative revenues of $6,586 and $12,116, at December 31, 2024 and 2023, respectively.

    Notes Receivable from Participants — Notes receivable from plan participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Delinquent participant loans are recorded as distributions based on the terms of the Plan document.

    ​

    3. FAIR VALUE MEASUREMENTS

    The fair values of investments are classified based on the lowest level of any input that is significant to the fair value measurement. The Plan used the following methods to determine fair value for purposes of the accompanying financial statements:

    Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Plan has the ability to access on the report date.

    Level 2 — Inputs (such as financial matrices, models, valuation techniques), other than quoted market prices included in Level 1, that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

    Level 3 — Inputs (such as professional appraisals, quoted prices from inactive markets that require adjustment based on significant assumptions or data that is not current, data from independent sources) that are unobservable for the asset or liability.

    Asset Valuation Techniques — The methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

    Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs. The following is a description of the valuation methodologies used for assets measured at fair value.

    Interest Bearing Cash — Held primarily in short-term money market commingled funds, which are valued at cost plus accrued interest.

    Mutual Funds — Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-ended mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

    6


    Table of Contents

    ​

    Common Stocks — Valued at the closing price reported on the active market on which the individual securities are traded.

    Self-directed Brokerage Accounts — Underlying investments consist of common stocks and mutual funds.

    Common-collective Trust Funds — Valued at the net asset value of units of a bank collective trust. The net asset value as provided by the trustee is used as a practical expedient to estimate fair value. The net asset value is based on the fair value of the underlying investments held by the fund less its liabilities. This practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported net asset value. Participant transactions (purchases and sales) may occur daily. Were the Plan to initiate a full redemption of the collective trust, the investment advisor reserves the right to temporarily delay withdrawal from the trust in order to confirm that securities liquidations will be carried out in an orderly business manner.

    Stable Value Fund — The Morley Stable Value Fund is a collective trust fund offered by the Principal Global Investors Trust Company whose objective is to provide preservation of capital, relatively stable returns consistent with its comparatively low risk profile and liquidity for benefit responsive payments. The fund is composed primarily of fully benefit-responsive investment contracts and is valued at the net asset value of units of the bank collective trust. The net asset value is used as a practical expedient to estimate fair value. This practical expedient would not be used if it is determined to be probable that the fund will sell the investment for an amount different from the reported net asset value. Participant transactions (purchases and sales) may occur daily. If the Plan initiates a full redemption of the collective trust, the issuer reserves the right to require 12 months’ notification in order to confirm that securities liquidations will be carried out in an orderly business manner.

    The following table provides the amount and corresponding level of hierarchy for the Plan’s investments that were measured at fair value on a recurring basis as of December 31, 2024:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

        

    Level 1

        

    Level 2

        

    Level 3

        

    Total

    Interest bearing cash

    ​

    $

    2,964

    ​

    $

    —

    ​

    $

    —

    ​

    $

    2,964

    Mutual funds

    ​

     

    109,564,402

    ​

     

    —

    ​

     

    —

    ​

     

    109,564,402

    Self-directed brokerage accounts

    ​

     

    6,706,231

    ​

     

    —

    ​

     

    —

    ​

     

    6,706,231

    Merit Medical Systems, Inc. common stock

    ​

     

    47,972,130

    ​

     

    —

    ​

     

    —

    ​

     

    47,972,130

    Total assets in the fair value hierarchy

    ​

    $

    164,245,727

    ​

    $

    —

    ​

    $

    —

    ​

    $

    164,245,727

    Investments measured at net asset value

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Common-collective trust funds

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    46,868,757

    Stable value fund

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    2,485,412

    Total Investments — at fair value

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    $

    213,599,896

    ​

    The following table provides the amount and corresponding level of hierarchy for the Plan’s investments that were measured at fair value on a recurring basis as of December 31, 2023:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

        

    Level 1

        

    Level 2

        

    Level 3

        

    Total

    Interest bearing cash

    ​

    $

    4,335,359

    ​

    $

    —

    ​

    $

    —

    ​

    $

    4,335,359

    Mutual funds

    ​

     

    94,608,147

    ​

    ​

    —

    ​

    ​

    —

    ​

    ​

    94,608,147

    Self-directed brokerage accounts

    ​

     

    3,696,816

    ​

    ​

    —

    ​

    ​

    —

    ​

    ​

    3,696,816

    Merit Medical Systems, Inc. common stock

    ​

     

    43,107,310

    ​

    ​

    —

    ​

    ​

    —

    ​

    ​

    43,107,310

    Total assets in the fair value hierarchy

    ​

    $

    145,747,632

    ​

    $

    —

    ​

    $

    —

    ​

    $

    145,747,632

    Investments measured at net asset value

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Common-collective trust funds

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    33,245,751

    Stable value fund

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    3,634,422

    Total Investments — at fair value

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    $

    182,627,805

    ​

    ​

    ​

    7


    Table of Contents

    ​

    4.     EXEMPT PARTY-IN-INTEREST TRANSACTIONS

    The Plan allows for transactions with certain parties who may perform services or have fiduciary responsibilities to the Plan, including the Company. Certain plan investments are shares of various mutual funds or money market accounts that are owned and managed by Fidelity Management Trust Company, who has been designated as investment custodian to the Plan. Certain Plan investments are shares of the Company's common stock. The Plan also issues loans to participants, which are secured by the vested balances in the participants’ accounts. Therefore, these transactions qualify as exempt party-in-interest transactions.

    At December 31, 2024 and 2023, the Plan held within participant accounts 495,990 and 567,500 shares, respectively, of the Company’s common stock, with a fair value of $47,972,130 and $43,107,310, respectively, and with a cost basis of $23,456,293 and $26,597,168, respectively. During the year ended December 31, 2024 purchases of shares by the Plan totaled $1,180,611 and sales of shares by the Plan totaled $5,302,403.

    Administrative revenues arise when investment managers return a portion of the investment fees to Fidelity Management Trust Company to offset the administrative expenses. Any excess resulting from this revenue sharing remains in an unallocated account from which future Plan expenses can be paid. During 2024, $56,351 was used to offset Plan expenses paid from this unallocated account. The Plan held undistributed administrative revenues of $6,586 and $12,116 at December 31, 2024 and 2023, respectively.

    ​

    5.     PLAN TERMINATION

    Although it has not expressed any intention to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions set forth in ERISA. In the event that the Plan is terminated, participants would become 100% vested in their accounts.

    ​

    6.     FEDERAL INCOME TAX STATUS

    Prior to 2016, the Plan used an individually-designed plan document that was covered by a series of prior favorable IRS determination letters as to its qualified form, the most recent of which was issued in 2011. Effective January 1, 2016, and prior to expiration of the Plan’s 2011 favorable IRS determination letter, the Plan was amended and restated through the adoption of an IRS pre-approved volume submitter plan document package that is covered by a favorable IRS advisory letter, dated June 30, 2020, in which the IRS determined that the form of the volume submitter document package later adopted by the Company met the applicable tax-qualification requirements. The Plan administrator believes that the Plan is currently designed and operated in compliance with the applicable requirements of the IRC and the Plan and related trust continue to be tax-exempt. Therefore, no provision for income taxes has been included in the Plan’s financial statements.

    ​

    8


    Table of Contents

    ​

    SUPPLEMENTAL SCHEDULE

    ​

    MERIT MEDICAL SYSTEMS, INC. 401(k) PROFIT SHARING PLAN

    EMPLOYER ID NO: 87-0447695

    PLAN NO: 001

    FORM 5500, SCHEDULE H, PART IV, LINE 4i — SCHEDULE OF ASSETS (HELD AT END OF YEAR)

    AS OF DECEMBER 31, 2024

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Description of Investment, Including

    ​

    ​

    ​

    ​

    ​

    ​

    Identity of Issue, Borrower,

    ​

    Maturity Date, Rate of Interest,

    ​

    ​

    ​

    ​

    ​

    ​

    Lessor or Similar Party

    ​

    Collateral, Par or Maturity Value

    ​

    Cost

    ​

    ​

    Current Value

    *

    Fidelity Cash Reserves

    ​

    Interest-bearing Cash Fund

    ​

    **

    ​

    ​

    2,964

    *

    Fidelity Money Market

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    3,193,969

    *

    Fidelity Government Money Market

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    6,586

    ​

    Artisan Mid Cap Fund

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    2,656,585

    ​

    Cohen & Steers Realty Shares

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    1,201,399

    *

    Fidelity Spartan 500 Index

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    24,980,005

    *

    Fidelity Inflation Protected Bond Index

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    862,151

    *

    Fidelity Total Market Index

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    643,396

    ​

    Grandeur Peak International Opportunities

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    467,412

    ​

    Janus Triton N

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    2,117,972

    ​

    JP Morgan Mid Cap Value Fund; Class A

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    2,566,069

    ​

    Matthews Emerging Market Small Companies

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    304,135

    ​

    Oakmark Fund; Class 1

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    5,784,905

    ​

    Oakmark International Fund; Class 1

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    1,502,452

    ​

    Oppenheimer Gold & Special Minerals Fund; Class A

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    1,140,773

    ​

    PIMCO Income Fund

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    2,226,507

    ​

    T Rowe Price Global Technology Fund

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    3,786,183

    ​

    T Rowe Price Personal Strategy Balances

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    15,122,628

    ​

    T Rowe Price Personal Strategy Growth

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    20,278,460

    ​

    T Rowe Price Personal Strategy Income

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    4,888,148

    ​

    Vanguard Developed Markets Index

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    1,338,986

    ​

    Vanguard Emerging Markets Index Admiral

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    954,661

    ​

    Vanguard Mid Cap Index Admiral

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    2,870,245

    ​

    Vanguard Small Cap Index Admiral

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    2,566,737

    ​

    Wasatch Small Cap Value Fund

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    3,058,444

    ​

    William Blair International Growth Fund, Class N

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    2,156,159

    ​

    Dodge & Cox Income Fund Class I

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    2,017,802

    *

    Fidelity Emerging Markets Fund

    ​

    Registered Investment Company

    ​

    **

    ​

    ​

    871,633

    ​

    Morley Stable Value Fund

    ​

    Stable Value Fund

    ​

    **

    ​

    ​

    2,485,412

    ​

    T Rowe Price Blue Chip Growth T2

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    7,014,698

    ​

    T Rowe Price Retirement 2005 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    316,145

    ​

    T Rowe Price Retirement 2010 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    190,578

    ​

    T Rowe Price Retirement 2015 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    172,775

    ​

    T Rowe Price Retirement 2020 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    139,792

    ​

    T Rowe Price Retirement 2025 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    2,782,067

    ​

    T Rowe Price Retirement 2030 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    7,086,185

    ​

    T Rowe Price Retirement 2035 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    5,943,067

    ​

    T Rowe Price Retirement 2040 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    6,235,306

    ​

    T Rowe Price Retirement 2045 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    5,586,142

    9


    Table of Contents

    ​

    ​

    T Rowe Price Retirement 2050 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    4,451,782

    ​

    T Rowe Price Retirement 2055 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    3,687,656

    ​

    T Rowe Price Retirement 2060 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    2,725,055

    ​

    T Rowe Price Retirement 2065 Fund B

    ​

    Common-Collective Trust Fund

    ​

    **

    ​

    ​

    537,509

    ​

    Self-directed Brokerage Account

    ​

    Self-directed Brokerage Account

    ​

    **

    ​

    ​

    6,706,231

    *

    Merit Medical Systems, Inc. Common Stock

    ​

    Common Stock (495,990 shares)

    ​

    **

    ​

    ​

    47,972,130

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Total assets held for investment purposes

    ​

    ​

    ​

    ​

    ​

    ​

    213,599,896

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    *

    Notes receivable from participants

    ​

    Interest rates of 4.25% to 9.5%, maturing through 2032

    ​

    **

    ​

    ​

    3,202,552

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Total

    ​

    ​

    ​

    ​

    ​

    $

    216,802,448

    ​

    *

    Party-in-interest

    **

    Cost information is not required for participant-directed investments and, therefore, is not included.

    ​

    ​

    10


    Table of Contents

    ​

    ​

    EXHIBIT INDEX

    ​

    Exhibit

    NumberDescription

    ​

    23.1Consent of Independent Registered Public Accounting Firm

    ​

    ​

    ​

    ​

    ​

    11


    Table of Contents

    ​

    SIGNATURE

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Merit Medical Systems, Inc. 401(k) Plan Administration and Investment Committee has duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    Merit Medical Systems, Inc.

    ​

    401(k) Profit Sharing Plan

    ​

    ​

    Date: June 27, 2025

    /s/ RAUL PARRA

    ​

    Raul Parra

    ​

    Chief Financial Officer and Treasurer

    ​

    ​

    ​

    ​

    12


    Get the next $MMSI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MMSI

    DatePrice TargetRatingAnalyst
    3/28/2025$120.00Overweight
    Analyst
    12/11/2024$103.00 → $120.00Equal Weight → Overweight
    Wells Fargo
    6/28/2024$96.00Outperform
    Robert W. Baird
    4/11/2024$88.00Buy
    CL King
    2/7/2024$87.00Neutral
    BofA Securities
    12/21/2023$100.00Hold → Buy
    Canaccord Genuity
    12/20/2022$73.00 → $72.00Buy → Hold
    Canaccord Genuity
    2/25/2022$73.00 → $72.00Outperform
    Raymond James
    More analyst ratings

    $MMSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025

      SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using th

      7/3/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Acquires Biolife Delaware, L.L.C.

      Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit's portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acquisition SOUTH JORDAN, Utah, May 20, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, t

      5/20/25 7:30:00 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis

      The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval from Health Canada. With this approval, Merit intends to begin immediate commercialization of the device throughout Canada with devices shipped from Merit's Toronto distribution center. Lo

      5/6/25 9:25:00 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    SEC Filings

    See more
    • SEC Form 11-K filed by Merit Medical Systems Inc.

      11-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

      6/27/25 4:22:13 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Merit Medical Systems Inc.

      144 - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      6/2/25 4:05:34 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Merit Medical Systems Inc.

      SD - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

      5/30/25 1:06:40 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO AND TREASURER Parra Raul Jr. exercised 15,181 shares at a strike of $59.43 and sold $1,423,219 worth of shares (15,181 units at $93.75) (SEC Form 4)

      4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

      6/17/25 5:57:11 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • President and CEO Lampropoulos Fred P. sold $38,244 worth of shares (400 units at $95.61), decreasing direct ownership by 0.04% to 1,045,628 units (SEC Form 4)

      4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

      6/12/25 6:11:05 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • New insider Smith Christian Adam claimed ownership of 11,543 shares (SEC Form 3)

      3 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

      6/11/25 10:18:28 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Merit Medical with a new price target

      Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00

      3/28/25 8:20:21 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously

      12/11/24 7:56:29 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Merit Medical with a new price target

      Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00

      6/28/24 8:04:44 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MMSI
    Financials

    Live finance-specific insights

    See more
    • Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025

      SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using th

      7/3/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Acquires Biolife Delaware, L.L.C.

      Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit's portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acquisition SOUTH JORDAN, Utah, May 20, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, t

      5/20/25 7:30:00 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

      First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Constant currency revenue; constant cu

      4/24/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Merit Medical Systems Inc.

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      11/14/24 11:05:03 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      2/13/24 5:09:38 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      2/12/24 5:32:43 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Merit Medical Announces Resignation of President, Joseph Wright

      SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI

      12/16/24 4:00:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Shareholders Elect Silvia M. Perez as New Director

      SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven

      5/16/24 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Executive Leadership Team Update

      Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit

      5/15/24 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care